Human isoprenoid synthase enzymes as therapeutic targets

Abstract

In the human body, the complex biochemical network known as the mevalonate pathway is responsible for the biosynthesis of all isoprenoids, which consists of a vast array of metabolites that are vital for proper cellular functions. Two key isoprenoids, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are responsible for the post-translational prenylation of small GTP-binding proteins, and serve as the biosynthetic precursors to numerous other biomolecules. The down-stream metabolite of FPP and GGPP is squalene, the precursor to steroids, bile acids, lipoproteins, and vitamin D. In the past, interest in prenyl synthase inhibitors focused mainly on the role of the FPP in lytic bone diseases. More recently pre-clinical and clinical studies have strongly implicated high levels of protein prenylation in a plethora of human diseases, including non-skeletal cancers, the progression of neurodegenerative diseases and cardiovascular diseases. In this review, we focus mainly on the potential therapeutic value of down-regulating the biosynthesis of FPP, GGPP, and squalene. We summarize the most recent drug discovery efforts and the structural data available that support the current on-going studies.

Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency

“…Because of the inclusion criteria, total cholesterol and LDL‐C levels were elevated in all participants of our study. However, although vitamin D and cholesterol share a common precursor (7‐dehydrocholesterol), patients with normal and low 25‐hydroxyvitamin D levels did not differ in baseline circulating levels of plasma lipids. This finding, which is in line with a neutral effect of vitamin D preparations on plasma lipids levels, as well as the lack of correlations between levels of 25‐hydroxyvitamin D and plasma lipids, suggest that vitamin D status plays a relatively small role in the regulation of lipid production and metabolism.…”

Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions

“…Hepatocytes are the major target for statin drugs where they inhibit HMG-CoA reductase enzyme. Statins, not only compete with the substrate in enzyme active site, but also they induce a conformational change in the enzyme's structure [56]. In addition, a series of processes leading to increased synthesis of NO by endothelial cells, reduction of cholesterol accumulation in macrophages, regression of atherosclerotic plaque, inflammatory process, inhibition of the platelet aggregation, alteration in intracellular calcium homeostasis and inhibition of tumor cells growth are all modulated by statins [57].…”

Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic

“…The inhibition of FPPS suppresses geranylation and farnesylation of several key proteins, which in turn activates the production of cell signaling molecules to stop osteoclastic activities [1-9]. Interestingly, in vitro studies also demonstrated that FPPS inhibition can decrease cell proliferation and migration, as well as induce apoptosis [1, 10]. In addition, a number of in vitro and clinical studies demonstrated that Zol efficiently inhibits basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) signaling, thus inhibiting blood vessel growth in a tumor [11, 12].…”